Posts by Mourabit Halima

From November 14 to 17, 2024, the Cellular Therapy and Immunotherapy Conference (CTI) was held in Hangzhou, China, bringing together global experts, scholars, and industry leaders in cellular and immunotherapy.…

In recent years, immunotherapy drugs, particularly PD-1/PD-L1 inhibitors, have gradually expanded from being used in later-line treatments to frontline therapy for non-small cell lung cancer (NSCLC). Perioperative immunotherapy has become a major focus in the field, with numerous breakthroughs reshaping the treatment landscape for operable NSCLC patients. However, challenges remain in patient selection, treatment regimens, and comprehensive perioperative management. As the year comes to an end, Oncology Frontier invited Dr. Changli Wang from Tianjin Medical University Cancer Institute and Hospital to review the progress and discuss the future prospects of perioperative immunotherapy for NSCLC in 2024.

At the end of 2024, the 2025 Essentials of CBCS & CSOBO Breast Cancer Diagnosis and Treatment Guidelines (hereafter referred to as the "New Little Red Book") was officially released during the 16th Shanghai Breast Cancer Symposium and Annual Meeting of the Shanghai Anti-Cancer Association Breast Cancer Committee. This updated edition provides fresh guidance for clinical breast cancer practices.

Editor’s Note: The 2024 Academic Conference on Precision Diagnosis and Treatment of Lung Cancer recently featured a presentation by Dr. Yan Huang from the Sun Yat-sen University Cancer Center, titled…

Editor’s Note: With the continuous advancement of medical research, the field of treatment for advanced triple-negative breast cancer (TNBC) is experiencing unprecedented transformation. During the recently held "Northern Breast Cancer…

With the ongoing advancements in breast cancer research, BRCA gene mutations, as a significant genetic risk factor for breast cancer, have attracted increasing attention. In this article, Dr. Songqing Ye from Fujian Provincial Hospital will provide a detailed discussion on the prognosis and treatment advances for BRCA-mutated breast cancer patients, covering the association between BRCA genes and breast cancer, the impact of genetic mutations on prognosis, treatment options, and a comprehensive review of the latest clinical research findings.

Editor's Note: At the end of 2024, the 2025 Essentials of CBCS & CSOBO Breast Cancer Diagnosis and Treatment Guidelines (hereafter referred to as the "New Little Red Book") was…

Editor’s Note: The Healthy China 2030 plan outlines a shift from a disease-centered approach to a health-centered development model, with a goal of increasing the five-year cancer survival rate by…